Extension of Irish sales and marketing agreement

Sinclair IS Pharma plc

Extension of sales and marketing agreement with Fannin Limited for Irish market

LONDON - 11 October 2011 - Sinclair IS Pharma Plc (AIM:SPH.L)  ("Sinclair IS" or "the Company"), the international specialty pharmaceutical company, announces that it has extended its exclusive agreement with Fannin Limited ("Fannin"), Ireland's leading medical sales and distribution company. Under the revised agreement, Fannin will assume responsibility for the sales and marketing of products currently marketed by Sinclair IS in the Republic of Ireland and will also promote a number of the Company's products in Northern Ireland, meaning that Sinclair IS will recognize a royalty income on the sale of these products going forwards.

Fannin has a long established dedicated hospital sales team that currently markets three Sinclair IS products. This deal extends the existing relationship to include the portfolio of products owned by Sinclair IS' local subsidiary Sinclair IS Pharma Ireland Limited, which IS Pharma acquired from Helsinn in January 2011. The agreement is also expected to lead to the launch of further products from Sinclair IS's portfolio in Ireland. On completion of the agreement, six employees from Sinclair IS will transfer to Fannin. The new arrangements will simplify the marketing of Sinclair IS products in Ireland.

Chris Spooner, CEO of Sinclair IS Pharma, commented "Fannin is the market leader of medical sales in Ireland and this agreement will significantly increase the promotion of our products. We look forward to Fannin launching new products into the Irish market and extending this relationship further in due course. The savings made by reducing the size of our Irish operation will enable us to invest further behind our key products in the UK, a key strategic focus following the recent merger with IS Pharma plc."

Ends

For further information please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Jefferies International Limited (NOMAD and Broker) Tel: +44 (0) 20 7029 8000

Julian Smith

Thomas Rider

FTI Consulting Tel: +44 (0) 20 7831 3113

Ben Atwell

Stephanie Cuthbert

Notes to Editors:

About Sinclair IS Pharma plc - www.sinclairispharma.com 

Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the

statements in this document that relate to future plans, expectations, events, performances and the like are

forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results

of events could differ materially from those described in the forward‐looking statements due to a variety of

factors.